NEO

NeoGenomics' stock has shown significant momentum in the past six months, with a 90-day gain above 73% and a 1-year rise of 145.2% as of September 17, 2026. Key events include strong Q2 2026 earnings reported on July 28, 2026, which saw revenue up 11.2% year-over-year and a net income of $2.2 million, beating analysts' EPS expectations and leading to raised full-year guidance. In August 2026, the company received Medicare coverage for its RaDaR ST minimal residual disease test, expanding market access. NeoGenomics also secured a court ruling invalidating key Natera patents, benefiting its RaDaR ST assay. The company's strategic focus on precision oncology growth, including NGS, MRD testing, and the launch of PanTracer, has driven investor interest. A Q3 Department of Justice (DOJ) settlement cash payment of $9.8 million to resolve False Claims Act allegations was noted as a near-term headwind. Despite positive news, the stock experienced some pullbacks in September 2026 due to profit-taking and valuation concerns.